PRoFESS® - The world's largest trial in prevention of recurrent stroke

PRoFESS®

• is one of the world’s largest trials in prevention of recurrent stroke with 20,332 patients enroled
• is the first head-to-head comparison of antiplatelet treatment for recurrent stroke prevention (ER-dipyridamole + ASA or clopidogrel)
• compares telmisartan vs. placebo on top of antiplatelet therapy
• uses a 2 x 2 factorial trial design that allows assessment of the contribution of each treatment tested
• is a multinational trial with substantial representation of all continents and races
• succeeded to enrol more than 2/3 of patients within 30 days of stroke onset
• has enroled a wide spectrum of patients with different ischaemic stroke subtypes (small vessel as well as large artery disease) and stroke severity (modified Rankin Scale 0–5)
• nearly 1/3 of patients were diabetic and more than 2/3 were hypertensive
• patients receive state of the art cardiovascular treatment (statin use in 47% of patients, BP well controlled at baseline with a mean BP of 144/84 mmHg)